SELEX

SELEX
Name	SELEX
Caption	In vitro selection workflow
Field	Molecular biology; Biotechnology

SELEX

Introduction

SELEX is an in vitro selection technique that isolates functional nucleic acid ligands from large combinatorial libraries using iterative binding, partitioning, and amplification steps. Pioneered in the late 20th century, the method links genotype and phenotype to discover molecules with high affinity and specificity, and it interfaces with platforms from academic labs at Massachusetts Institute of Technology to industrial groups at Pfizer, Roche, and GlaxoSmithKline. Key names and nodes associated with its development and use include institutions such as Harvard University, Stanford University, University of Cambridge, University of Oxford, and consortia like the Human Genome Project and projects funded by National Institutes of Health and Wellcome Trust.

History and Development

Early conceptual roots trace to molecular evolution studies at places like California Institute of Technology and laboratories influenced by researchers affiliated with Cold Spring Harbor Laboratory and Max Planck Society. The technique matured alongside advances by teams connected to Scripps Research Institute, Yale University, Columbia University, and industrial research at AstraZeneca and Novartis. Intellectual environments at centers such as European Molecular Biology Laboratory, The Rockefeller University, and Tokyo University accelerated methodological refinements. Funding and dissemination through agencies including the European Research Council, Japan Society for the Promotion of Science, and Bill & Melinda Gates Foundation supported applications spanning diagnostics in companies like Abbott Laboratories and therapeutics explored at Amgen and Bristol-Myers Squibb.

Methodology and Variants

The canonical workflow involves library synthesis, target exposure, separation of bound from unbound sequences, amplification by polymerase chain reaction techniques developed at Promega Corporation and applied using instruments by Thermo Fisher Scientific and Bio-Rad Laboratories, and iterative enrichment monitored by sequencing technologies from Illumina and Oxford Nanopore Technologies. Variants emerged such as Cell-SELEX implemented in cell biology labs affiliated with Johns Hopkins University and UCSF, In vivo selection trials influenced by studies at National Institutes of Health Clinical Center, and Toggle-SELEX inspired through collaborations with teams at Massachusetts General Hospital and Dana-Farber Cancer Institute. High-throughput adaptations integrate microfluidic devices from groups tied to MIT Media Lab and droplet platforms associated with Harvard Medical School, while computational selection and design use algorithms developed in labs at Carnegie Mellon University and ETH Zurich. Other derivative methods include Capture-SELEX used in biotechnology startups like Twist Bioscience, Spiegelmer strategies connected to NOXXON Pharma AG, and X-SELEX formats explored at University of Tokyo.

Applications

Therapeutic aptamers resulting from these procedures have been developed by firms such as Regeneron Pharmaceuticals and tested in clinical trials overseen by regulatory bodies like Food and Drug Administration and European Medicines Agency. Diagnostic reagents leveraging selected ligands are employed by companies including Siemens Healthineers and Roche Diagnostics for biomarker capture in workflows used at hospitals like Mayo Clinic and research centers such as Cleveland Clinic. Research tools derived via SELEX inform structural studies carried out at facilities including Brookhaven National Laboratory and Argonne National Laboratory and complement imaging performed at National Institutes of Health intramural programs. Environmental biosensing and biodefense applications have engaged agencies like Centers for Disease Control and Prevention and international collaborations under World Health Organization. Agricultural and food-safety implementations have been trialed in partnerships with USDA laboratories and corporations like Nestlé.

Advantages and Limitations

Advantages highlighted in reviews from journals associated with Nature Publishing Group and Cell Press include rapid discovery cycles used by biotech incubators in Silicon Valley, ease of chemical modification practiced by teams at DuPont and BASF, and compatibility with next-generation sequencing workflows from PacBio and Illumina. Limitations documented in studies from groups at Imperial College London and University of Edinburgh include biases introduced during amplification linked to polymerase vendors like New England Biolabs, challenges in translating in vitro affinity to in vivo efficacy encountered by clinical units at Mayo Clinic, and intellectual property complexities litigated in cases involving companies such as Theranos and Genentech. Scalability and cost issues have been addressed by collaborations with platform developers at Agilent Technologies and Beckman Coulter.

Ethical, Safety, and Regulatory Considerations

Regulatory oversight involves agencies such as Food and Drug Administration, European Medicines Agency, and national regulators within Ministry of Health (Japan) and Health Canada, while ethical review occurs through institutional boards at Beth Israel Deaconess Medical Center and university ethics committees at University of Toronto. Dual-use concerns have prompted engagement with policy groups including National Academies of Sciences, Engineering, and Medicine and think tanks like RAND Corporation and Chatham House. Biosafety practices align with guidelines from World Health Organization laboratories and containment protocols in research facilities accredited by Association for Assessment and Accreditation of Laboratory Animal Care International. Intellectual property and access debates feature stakeholders such as World Intellectual Property Organization and public-interest organizations like Doctors Without Borders.

Category:Molecular biology